Posts in Management
Martin Lehr

Mr. Lehr is the Co-founder and CEO of Context Therapeutics. In addition, Mr. Lehr is a member of the Scientific Advisory Board of Integral Molecular, an antibody discovery company.  Previously, Martin was part of the founding team at Osage University Partners, a venture capital fund focused on academic spinouts from leading research institutions. At Osage, Martin focused on early stage oncology and rare disease opportunities. Prior to Osage, Martin conducted research at the Sloan Kettering Institute in DNA repair and at the Children’s Hospital of Philadelphia in thrombosis and hemostasis.  In addition to his role at Context, Martin is the Director of Philly BioBreak, a biotech executive peer group with over 2,500 active members across the United States. He holds an M.A. in Biotechnology from Columbia University and a B.A. in Economics from the University of Pennsylvania.

+ LinkedIn

Read More
Tarek Sahmoud, MD, PhD

Dr. Sahmoud is President of OncoStrategy, a boutique clinical development consultancy and is consulting Chief Medical Officer to Context Therapeutics. Dr. Sahmoud has more than 25 years of experience in oncology drug development and medical affairs, most recently as Chief Medical Officer of H3 Biomedicines. Tarek also held senior clinical development positions at Celgene, Novartis, and AstraZeneca. During his career, Tarek has either led or supported global drug development programs for several novel oncology drugs in multiple indications, including adjuvant breast cancer (Arimidex), hormone receptor positive breast cancer (Kisqali and Afinitor), resulting in successful global registrations. His experience also includes the development and leading of global and US medical affairs teams, multi-disciplinary teams of physicians and clinical scientists, as well as serving as on the protocol review committee of a number of companies.

Dr. Sahmoud received his medical degree from Cairo University Medical School, Egypt and a Ph.D. in biostatistics from University Bordeaux II, France.

Read More
Christopher Beck, MBA

Mr. Beck is a pharmaceutical leader with a proven track record in strategy execution. His 30-year career spans a spectrum of disciplines including:  program/resource management; merger and acquisition integration; and cross-functional team leadership.  He joins Context Therapeutics from Aevi Genomics, where he was the VP of Program Management. Previously, Mr. Beck was VP of Schedule and Resource Decision Analytics at Shire Pharmaceuticals, and created Shire’s first global project management and resource capacity planning capability.   Adding to the ten years of pharmaceutical experience at Shire, Mr. Beck envisioned, created and led global project and resource management organizations at Merck and Co, Astra Pharmaceuticals and AstraZeneca Inc.  Earlier in his career, Mr. Beck forged his project management foundation at GE Aerospace as a project scheduler. 

Mr. Beck holds a B.S. Business Administration degree, from Drexel University and an MBA from Pennsylvania State University.

 

Read More
Bill Rencher, PhD

Dr. Rencher is President of Drug and Device Development Solutions LLC (D3S), a boutique Chemistry Manufacturing Controls (CMC) consulting firm. Through D3S, Dr. Rencher is consulting Head of CMC at Context Therapeutics. His expertise is in pharmaceutical sciences, including product development, drug and product manufacturing, clinical supply distribution, and quality/regulatory.  Over his 30+ year career he has been employed by SKB, McNeil, Schering and the CONRAD Program; holding positions as group leader through director.  He holds a B.S. in Pharmacy and Ph.D. in Pharmaceutical Sciences from the University of Kentucky. 

Read More
Deepak S. Lala, PhD

Dr. Lala has 20 years of drug discovery experience at a strategic and operational level in large and small pharmaceutical companies. Before Context he was Executive Director, Biology at Vitae Pharmaceuticals (affiliate of Allergan Inc.) where he played a key role in advancing seven compounds into clinical studies (Phase I/II) for multiple indications. He was also responsible for building and executing translational biomarker approaches for human proof of mechanism studies. Before Vitae, he was Associate Director at Pfizer where he led an anti-fibrosis program leading to a clinical candidate and demonstrating the translatability of preclinical fibrotic biomarkers in the clinic. Prior to that he was a Group Leader at Pharmacia where he created a drug discovery platform to initiate new programs across different therapeutic areas. Before that he worked at Ligand Pharmaceuticals focusing on nuclear receptors as drug targets. Dr. Lala earned his Ph.D. in Cell and Molecular Biology from Augusta University. He was awarded a Howard Hughes Medical Institute (HHMI) fellowship to carry out post-doctoral training at Duke University Medical Center.

 

Read More
Tasir Haque, PhD

Dr. Tasir Haque is Head of Chemistry at Context Therapeutics.  Prior to joining Context, Tas was a Principal Scientist in Immunology Chemistry at Bristol-Myers Squibb, where he focused on advancing small molecule programs to IND status. His background at BMS includes drug discovery programs in several therapeutic areas including Oncology, Metabolic Diseases, and Cardiovascular Diseases. Tas has extensive experience with both small molecule and linear and cyclic peptide research. Earlier in his career, Tas was a member of the Directed Parallel Synthesis medicinal chemistry team at DuPont Pharmaceuticals, where he focused on Anti-Infectives. Tas is an inventor on multiple patents and has written and reviewed articles in several peer-reviewed journals. He holds a B.S. in Chemistry from the University of Michigan, a Ph.D. in Organic Chemistry from the University of Wisconsin, and was an NIH postdoctoral fellow at the University of California, Berkeley. 

+ LinkedIn

Read More